Recipient/donor contradictory genotypes with impact on drug pharmacogenetics after liver transplant: A deadly gift?

Pharmacogenetics and Genomics

Volumn 24, Issue 10, 2014, Pages 527-529

  Serdjebi, Cindy ^a,c   Ciccolini, Joseph ^a,c   Fina, Frederic ^a,c   Delarue, Arnauld ^b   Verschuur, Arnauld ^b   Lacarelle, Bruno ^c   Ouafik, L'houcine ^a,c   André, Nicolas ^b,c  

^a INSERM   (France)

^b TIMONE HOSPITAL   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Cytarabine; Cytidine deaminase; Liver transplantation; Pharmacogenetics; Toxicity

Indexed keywords

CYTARABINE; CYTIDINE DEAMINASE; ANTINEOPLASTIC ANTIMETABOLITE;

ANEMIA; ARTICLE; BURKITT LYMPHOMA; CASE REPORT; CDA GENE; CHILD; CYTIDINE DEAMINASE DEFICIENCY; DISEASE SEVERITY; DRUG DETOXIFICATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME DEFICIENCY; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; GERM LINE; GRAFT RECIPIENT; HOMOZYGOSITY; HUMAN; LIVER BIOPSY; LIVER TRANSPLANTATION; MELENA; NEUTROPENIA; ORGAN DONOR; PHARMACOGENETICS; PHENOTYPE; PRESCHOOL CHILD; RECTUM HEMORRHAGE; THROMBOCYTOPENIA; ADVERSE EFFECTS; DEFICIENCY; DOSE RESPONSE; GENETICS; GERMLINE MUTATION;

ANTIMETABOLITES, ANTINEOPLASTIC; BURKITT LYMPHOMA; CHILD, PRESCHOOL; CYTARABINE; CYTIDINE DEAMINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GERM-LINE MUTATION; HUMANS; LIVER TRANSPLANTATION; POLYMORPHISM, GENETIC;

EID: 84916195776     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000076     Document Type: Article

References (9)

1. Ciccolini J, Dahan L, André N, Evrard A, Duluc M, Blesius A, et al. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J Clin Oncol 2010;28:160-165.
2. Ciccolini J, Evrard A, M'Batchi L, Pourroy B, Mercier C, Iliadis A, et al. CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations. Pharmacogenomics 2012;13:393-397.
3. Evrard A, Lacarelle B, Ciccolini J. Severe or lethal toxicities with nucleosidic analogs: time for action. Pharmacogenomics 2013;14:227-230.
4. Aini W, Miyagawa-Hayashino A, Ozeki M, Tsuruyama T, Tamaki K, Uemoto S, Haga H. Frequent hepatocyte chimerism in long-term human liver allografts independent of graft outcome. Transpl Immunol 2013;28:100-105.
5. Idilman R, Erden E, Kuzu I, Ersoz S, Karasu Z, Karayalcin K, et al. Recipientderived hepatocytes in sex-mismatched liver allografts after liver transplantation: early versus late transplant biopsies. Transplantation 2004;78:1647-1652.
6. Sun Z, Williams GM. Host stem cells repopulate liver allografts: reverse chimerism. Chimerism 2011;2:120-122.
7. Henriette Tanja L, Guchelaar HJ, Gelderblom H. Pharmacogenetics in chemotherapy of colorectal cancer. Best Pract Res Clin Gastroenterol 2009;23:257-273.
8. Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin 2009;59:42-55.
9. Lee SY, McLeod HL. Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application. J Pathol 2011;223:15-27.